Publicaciones (55) Publicaciones de JUAN VERDAGUER AUTONELL

2023

  1. A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 48

  2. Mutual modulation of gut microbiota and the immune system in type 1 diabetes models

    Nature Communications, Vol. 14, Núm. 1

  3. NOD mouse dorsal root ganglia display morphological and gene expression defects before and during autoimmune diabetes development

    Frontiers in Endocrinology, Vol. 14

  4. Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis

    STAR Protocols, Vol. 4, Núm. 4

2021

  1. CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model

    Frontiers in Immunology, Vol. 12

2020

  1. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma

    Australasian Journal of Dermatology, Vol. 61, Núm. 2, pp. e200-e207

  2. Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming

    Frontiers in Endocrinology, Vol. 11

2019

  1. B-Lymphocyte Phenotype Determines T-Lymphocyte Subset Differentiation in Autoimmune Diabetes

    Frontiers in immunology, Vol. 10, pp. 1732

2018

  1. Phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in human type 1 diabetes by apoptotic mimicry

    Frontiers in Immunology, Vol. 9, Núm. FEB

  2. Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. B-cell anergy induces a Th17 shift in a novel B lymphocyte transgenic NOD mouse model, the 116C-NOD mouse

    European Journal of Immunology, Vol. 46, Núm. 3, pp. 593-608

  2. B-lymphocytes expressing an Ig specificity recognizing the pancreatic β-cell autoantigen peripherin are potent contributors to type 1 diabetes development in NOD mice

    Diabetes, Vol. 65, Núm. 7, pp. 1977-1987

  3. El abordaje de la inmunoterapia específica de las enfermedades autoinmunes a través de la nanomedicina

    Endocrinologia y Nutricion, Vol. 63, Núm. 9, pp. 437-439

2015

  1. Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes

    Clinical and Experimental Immunology, Vol. 180, Núm. 2, pp. 207-217

  2. Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes

    PLoS ONE, Vol. 10, Núm. 6

2014

  1. Cyclin D3 promotes pancreatic β-cell fitness and viability in a cell cycle-independent manner and is targeted in autoimmune diabetes

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 33

  2. In vivo detection of peripherin-specific autoreactive B cells during type 1 diabetes pathogenesis

    Journal of Immunology, Vol. 192, Núm. 7, pp. 3080-3090

  3. Nous conceptes sobre la diabetis autoimmunitària

    Treballs de la Societat Catalana de Biologia, Núm. 65, pp. 33-38

2013

  1. Efferocytosis Promotes Suppressive Effects on Dendritic Cells through Prostaglandin E2 Production in the Context of Autoimmunity

    PLoS ONE, Vol. 8, Núm. 5

  2. Latent autoimmune diabetes in adults is perched between type 1 and type 2: Evidence from adults in one region of spain

    Diabetes/Metabolism Research and Reviews, Vol. 29, Núm. 6, pp. 446-451